Tyrosine kinase fibroblast growth factor receptor (FGFR),which is aberrant in various cancer types,is a promising target for cancer therapy[1-4].Thus,discovery of potent and selective FGFR inhibitors is an urgent need in cancer treatment.Currently,several FGFR-selective inhibitors have progressed into clinical trials (Figure 1)[5-7].